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BACKGROUND: Patient accrual into cancer clinical trials remains at low levels. This survey elicited attitudes and practices of cancer
clinicians towards clinical trials.
METHOD: The 43-item Clinicians Attitudes to Clinical Trials Questionnaire was completed by participants in an intervention study
aimed at improving multi-disciplinary involvement in randomised trials. Responses from 13 items were summed to form a research-
orientation score.
RESULTS: Eighty-seven clinicians (78%) returned questionnaires. Physicians, more often than surgeons, chose to prioritise prolonging a
patient’s life, recruited X50% of patients into trials and attended more research-focussed conferences. Clinicians at specialist centres
were more positive about trials with no-treatment arms than those at district general hospitals, more likely to believe clinician, rather
than patient reluctance to participate was the greater obstacle to trial accrual, and preferred national and international to local
recognition. Clinicians belonging to breast and colorectal teams were less disappointed about not enrolling patients in trials and more
accepting of no-treatment arm trials. Research orientation was higher in physicians than surgeons and higher in specialist centres than
district hospitals.
CONCLUSIONS: This study provides greater understanding of clinicians’ attitudes to trials. Results have been used to inform training
interventions for clinicians targeting the problem of low and selective accrual.
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The randomised controlled trial (RCT) remains the gold-standard
by which new cancer treatments are assessed and through which
therapeutic progress is made. Despite the need to develop new
cancer therapies, accrual of patients into such trials remains low
with fewer than 5% of cancer patients participating (Tejeda et al,
1996; Christian and Trimble, 2003; Murthy et al, 2004; Somkin
et al, 2005; Elting et al, 2006). Even in centres running trials
suitable for a particular patient group such as women with limited,
local breast cancer or other solid tumours, participation of those
eligible is only 12–30% (Elting et al, 2006; Maslin-Prothero, 2006).
As well as increasing the time needed to complete studies this low
recruitment means that randomised patients may differ signifi-
cantly from those who do not take part. This risks undermining
the study results by making it difficult to draw generally applicable
conclusions (Elting et al, 2006). Several US and European
organisations acknowledge that slow accrual hampers the timely
release of new therapies into the clinic. For example, only about
60% of US National Cancer Institute (NCI)-sponsored trials are
completed and published (Nass et al, 2010). In addition, certain
patient populations are under-represented, resulting in the recent
development of several national and international programmes to
address the problem of slow and selective recruitment (EDICT,
2008; Lally and Crome, 2010; Seifer et al, 2010).
Studies have found that the majority of clinicians favour clinical
trials, viewing them as a source of high-quality patient care, and as
a benefit to themselves, their institutions, and to society (Weinberg
et al, 2004; Somkin et al, 2005). However, there are two main
problems needing attention if trial participation is to be increased:
first that clinicians do not offer trials to all eligible patients (Kaas
et al, 2005), and second that some patients offered seemingly
appropriate trials refuse participation (Siminoff et al, 2000).
Reducing clinician gate-keeping and broadening the range of
patients to whom trials are offered is challenging, but improving
clinicians’ communication skills when explaining trials has the
potential to resolve patients’ concerns and increase the likelihood
of their participation. A review of NCI-sponsored trials noted the
importance of changing physicians’ perspectives so that they will
be more likely to encourage their patients to participate in clinical
trials (Nass et al, 2010). Understanding more about clinicians’
attitudes and practices in this area is necessary and timely, if
recruitment is to be improved.
Research shows that clinicians often adopt stringent, idiosyn-
cratic criteria when selecting the patients to whom they offer trials,
over and above the criteria delineated in trial protocols. In
particular, some clinicians only select patients with even better
health status and prognosis than demanded by the protocol
(Antman et al, 1985; Hjorth et al, 1992; Rahman et al, 1997; Cottin
et al, 1999; Siminoff et al, 2000) or choose not to offer trial
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sparticipation on putative compassionate grounds (Fayter et al,
2007). Clinicians may hesitate to inform patients of trials, based
on their own attitudes and beliefs about a patient’s willingness
to participate, ability to understand the trial, or adhere to the
protocol (EDICT, 2008). This is despite 83% of patients being
potentially willing to participate if given full trial information
(Jenkins et al, 2010). Other clinicians are reluctant to enrol patients
in trials if the treatment concerned may result in extra side effects
(White et al, 2008). If older and sicker patients are not included in
clinical trials then trial participants are likely to have better
outcomes than would be seen were the new treatments offered in
normal clinical practice.
Perhaps unsurprisingly, assessments of clinicians’ attitudes
show that many tend to be clinically, rather than research
oriented, believing that individual benefit for their patient is more
important than improving future therapy (Caldwell et al, 2005).
Some indicate that the main reason for including their patients in
trials is so that they receive state of the art treatment (Joffe and
Weeks, 2002), and trials focussing on quality of life outcomes tend
to have better accrual rates (Hjorth et al, 1996).
A lack of confidence in explaining clinical trials to patients and
obtaining informed consent is a barrier to some clinicians
(Tournoux et al, 2006; Fayter et al, 2007). Clinicians are reticent
to enrol patients who may have difficulty understanding what the
trial involves (Weinberg et al, 2004). If the trial arms are not
equally attractive or there is a no-treatment arm, this too may
prove a disincentive (Maslin-Prothero, 2006). Furthermore, if the
protocol is overly arduous to implement (e.g., requiring substantial
time or resource commitments from the clinician or their
organisation) clinicians are unlikely to recruit a large number of
patients (Hjorth et al, 1996; Ellis et al, 1999; Grunfeld et al, 2002;
Weinberg et al, 2004; Tournoux et al, 2006; Fayter et al, 2007).
Some patients also may have a problem with understanding
the concept of randomisation (Jenkins et al, 2002) and may
struggle to accept clinical equipoise, for example, in the case of a
placebo or no-treatment arm trial (Robinson et al, 2005).
Furthermore, clinicians may explain these concepts in ways that
patients may find hard to understand or even find threatening
(Jenkins et al, 2002).
Despite these barriers, the majority of medical and clinical/
radiation oncologists do report enrolling patients into clinical
trials (Fallowfield et al, 1997). Interestingly, different specialties
within oncology have different accrual rates, although which
specialties accrue more is not consistent. In one survey of UK
clinicians, medical oncologists generally placed more emphasis
on research than did surgical or clinical oncologists, and felt
greater pressure to participate in trials (Fallowfield et al, 1997). In
Australia, medical and surgical oncologists participated more in
clinical trials than radiation oncologists (Ellis et al, 1999). In the
United States, medical and paediatric oncologists reported the
lowest rates of patient enrolment in trials (Joffe and Weeks, 2002),
although a more recent study showed greater recruitment among
medical and radiation oncologists than among surgeons (Klabunde
et al, 2011). A further study found no differences in attitudes
towards clinical trials between surgeons and physicians, although
this was not limited to oncologists (McCulloch et al, 2005). An
understanding of how differences between specialists affect trial
recruitment may help promote accrual across specialties. Some
suggested reasons for differences are type of education, concept of
medicine, individual or professional aims, affiliation with aca-
demic or research groups, or particular working environment
(Castel et al, 2006), while Klabunde et al (2011) suggest that
specialty type, involvement in teaching, affiliation with a Commu-
nity Clinical Oncology Programme or with a National Cancer
Institute-designated cancer centre were important.
Greater understanding of clinicians’ attitudes to clinical trials is
needed to target the problem of low and selective accrual (Castel
et al, 2006). The present survey elicited clinician attitudes towards
clinical trials in their practice using a modified version of the
Physician Orientation Profile (Taylor and Kelner, 1987). The aims
were to assess clinician responses for differences by specialty, type
of hospital, type of team, and geographic region and to estimate
a research-orientation score for each clinician, again looking
for differences between groups. The data used for this study are a
component of a large Cancer Research UK funded prospective
study examining multidisciplinary team members’ communication
skills and involvement in clinical trials; primarily randomised,
controlled, phase 3 trials. The main study examined different
aspects of trial recruitment, including involvement of individual
team members in clinical trials; assessment of the clarity of health
professionals’ communication by patients recruited into clinical
trials, and attitudes towards RCTs (Figure 1). The attitudes of
patients to RCTs (Jenkins et al, 2010) and that of clinicians to
RCTs were collected for each multi-disciplinary team (MDT) to
provide an evidence-based argument for encouraging clinicians to
consider approaching more patients about trials. The clinician data
are presented here.
MATERIALS AND METHODS
Sample
Recruitment of clinicians (senior doctors) within oncology MDTs
(also known as interdisciplinary tumour boards) was a joint effort
between the Cancer Research UK Psychosocial Oncology Group
and the Wales Cancer Trials Network. Twenty-two MDTs
throughout Wales participated in the larger communication study.
The study had ethical approval from the South East Wales Local
Research Ethics Committee (ref: 07/WSE03/17). Teams were
randomised to receive communication training or to go on a
waiting list. Consultant (attending) surgeons, oncologists, chest
physicians, and haematologists were asked to complete ques-
tionnaires examining their attitudes to trials and their involvement
in trials before randomisation.
Materials
The Clinicians’ Attitudes to Clinical Trials of Cancer Therapy
Questionnaire is a modified version of the 30-item, binary option,
Physician’s Orientation Profile (Taylor and Kelner, 1987) and has
been used before by this research group (Fallowfield et al, 1997).
Items on this questionnaire are classified into five subscales
assessing various aspects of clinicians’ attitudes towards their
clinical and scientific work, specifically primary allegiance,
professional activities, decision-making under uncertainty, per-
ceived professional rewards, and peer group influence. The
questionnaire used in this study had 43 items and is very similar
to the 45-item questionnaire used by Fallowfield et al (1997).
Professional information (specialty, MDT cancer site, etc.) was also
collected for each clinician.
Derivation of research-orientation score
Two senior researchers (LF and VJ) independently chose items
from the questionnaire on the basis of their face validity for the
construct ‘Research Orientation’. Each researcher independently
chose 18 items from the original 43 with 100% consistency. The
items were recoded where necessary to provide binary responses
(0 out of 1) with 1 indicative of a research orientation. The chosen
items were subjected to statistical scrutiny to assess their factorial
validity and reliability. Classical principal components analysis
(PCA) was undertaken based on the binary responses to these
18 questions (D’Agostino Snr, 2005) with the pragmatic aim
of identifying items, which were well correlated and could be
hypothesised to represent one or more underlying factors or
constructs. Following PCA, a scree plot suggested a single
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scomponent solution was most suitable for these items (first
component eigenvalue 5.79, 32.15% of variance; second compo-
nent 2.03, 11.29% of variance). Items 6, 7, 8, 12, 13, 16, 17, 27, 28,
31, 35, 36, and 40 loaded onto the first component with loadings
from 0.47 to 0.83. Item 11 loaded at 0.32 and items 5, 22, 32, 43
loaded at o0.30.
All 18 items were then examined for internal consistency.
Cronbach’s a was found to be 0.83, and low item-total correlations
were found for items 5 (0.02), 11 (0.27), 22 (0.13), 32 (0.13), and
43 (0.20), suggesting that a would increase by removing these
items. Items 5, 11, 22, 32, and 43 were removed and Cronbach’s
a recalculated for the 13 items (a¼0. 89). A second PCA on these
remaining 13 items showed again that these items loaded onto one
component explaining 44.4% of the variance (loadings 0.49–0.84).
The responses from the remaining 13 items were summed to form
a research-orientation score.
Analysis
Question response was linked to possible explanatory variables
through logistic regression. Random effects were used to account
for within-team correlations, although in general these correlations
were low. As the number of clinicians returning questionnaires was
relatively small compared with the number of questions, and with
conservatism introduced because of within-team correlations,
there is little scope for multiplicity adjustments. Thus, significance
levels related to individual questions should be treated with
caution and seen as primarily providing an ordering of observed
discriminatory ability. The analysis of the derived research-
orientation score, which represented the sum of 13 questions,
was based on continuation ratio ordinal regression analysis, with
use of a complementary log–log link. The more flexible
continuation ratio model was preferred to a binomial regression
because of the variability between questions in the proportion of
‘research oriented’ answers.
RESULTS
Out of the 111 clinicians approached, 87 (78.4%) returned
questionnaires. The sample was formed of 47 surgeons, 28
oncologists, 9 haematologists, and 3 chest physicians. These
clinicians belonged to MDTs for the following cancers: breast
(25; 31%), colorectal (15; 17%), gynaecology (8; 9%), haematology
(10; 11.5%), lung (6; 7%), lymphoma (3; 3%), upper gastro-
intestinal (10; 11.5%), and urology (10; 11.5%). Responses to each
item on the questionnaire, and differences in responses by separate
groupings (physician vs surgeon; specialist hospital (large teaching
or city hospital) vs district general hospital (DGH) (community
hospital); breast and colorectal teams vs others) are shown
in Table 1.
Differences by specialty
Table 2 shows the questionnaire items that best distinguished
between physicians (oncologists, haematologists, and chest physi-
cians) and surgeons. Physicians more frequently endorsed
prolonging a patient’s life over improving quality of life. They
were also more likely to report recruiting 50% or more of their
patients into clinical trials and attending conferences focussed on
research rather than clinical issues. These differences suggest
physicians may be more research focussed than their surgical
counterparts.
Differences by centre
Table 3 shows the questionnaire items best differentiating
clinicians who worked in a specialist cancer centre from those
who worked in a DGH. Those working at a specialist centre were
less reluctant to randomise patients into trials with no-treatment
arms, more likely to believe that clinician reluctance (as opposed
to patient reluctance) to participate was a major obstacle to trial
accrual, and were more likely to wish to be well known among
Pre workshop patient and team
member audits
(for either 6 or 12 months)
Residential workshop
Six-month post workshop patient 
and team audits
Questionnaires: clinicians’ attitudes to trials*; 
previous communication skills training; 
involvement in trials; discussing aspects and 
types of trials and colleagues’ roles in trial 
discussions
Surveys: patients’ attitudes to trials; clarity and 
consistency of trial information; why patients 
accepted or declined trial entry
Patients eligible; N approached; N accepted 
trial entry
1.5-day learner-centred residential course; 
didactic evidence-based presentations; team 
roleplays with simulated patients and feedback;
group discussions
Patients eligible; N approached; N accepted 
trial entry
Team members involvement in trials 
questionnaire
Teams:
Patients:
Audit:
Workshop:
Audit:
Figure 1 Overall ‘Teams Talking About Trials’ project. *Data presented in this paper.
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sTable 1 Differences in response in physicians vs surgeons, specialist hospital vs district general and breast and colorectal teams vs other teams
Overall
Sample (%)
Physician (%)
(n¼40)
Surgeon (%)
(n¼47)
DGH (%)
(n¼33)
Specialist (%)
(n¼54)
Breast/colorectal
(%) (n¼40)
Other cancer type
(%) (n¼47)
Q1. Ideally, clinicians are able to increase survival and improve the quality of patients’ lives. In cases where only one can be achieved at the cost of the other, I feel more satisfied when I can:
(a) improve patients’ quality of life 71 (83.5%) 29 (74.3) 42 (91.3) 27 (84.4) 44 (83.0) 32 (82.1) 39 (84.8)
(b) prolong patients’ lives 14 (16.5%) 10 (25.6) 4 (8.7) 5 (15.6) 9 (17.0) 7 (17.9) 7 (15.2)
Q2. If a patient refuses to participate in a randomised clinical trial that I suggest, I would:
(a) treat the patient off the study 87 (100%) — — — — — —
(b) refer the patient to another clinician 0 (0%) — — — — — —
Q3. In general, when I initiate a treatment for cancer, I am:
(a) optimistic that the treatment will work 80 (93.0%) 38 (97.4) 42 (89.4) 31 (93.9) 49 (92.5) 37 (92.5) 43 (93.4)
(b) pessimistic that the treatment will work 6 (7.0%) 1 (2.6) 5 (10.6) 2 (6.1) 4 (7.5) 3 (7.5) 3 (6.5)
Q4. In my hospital the pressure to participate in a randomised clinical trial is relatively:
(a) low 58 (68.2%) 21(53.8) 37 (80.4) 26 (78.8) 32 (61.5) 29 (74.4) 29 (63.0)
(b) high 27 (31.8%) 18 (46.2) 9 (19.6) 7 (21.2) 20 (38.5) 10 (25.6) 17 (37.0)
Q5. I enter the following amount of my potentially eligible patients into randomised clinical trials:
(a) under 50% 66 (75.9%) 25 (62.5) 41 (87.2) 27 (81.8) 39 (72.2) 31 (77.5) 35 (74.5)
(b) 50% or more 21 (24.1%) 15 (37.5) 6 (12.8) 6 (18.2) 15 (27.8) 9 (22.5) 12 (25.5)
Q6. My primary commitment is to:
(a) future generations of patients (society) 9 (10.7%) 4 (10.3) 5 (11.1) 3 (9.1) 6 (11.8) 7 (18.4) 2 (4.3)
(b) present patients (individuals) 75(89.3%) 35 (89.7) 40 (88.9) 30 (90.9) 45 (88.2) 31 (81.6) 44 (95.6)
Q7. When faced with a controversial treatment decision, I feel most comfortable when:
(a) I make the decisions 11 (12.8%) 4 (10.3) 7 (14.9) 4 (12.1) 7 (13.2) 6 (15.0) 5 (10.9)
(b) the decisions are made by the trial protocol 8 (9.3%) 4 (10.3) 4 (8.5) 2 (6.1) 6 (11.3) 3 (7.5) 5 (10.9)
(c) the decision is made by the Multi-Disciplinary Meeting 67 (77.9%) 31 (79.5) 36 (76.6) 27 (81.8) 40 (75.5) 31 (77.5) 36 (78.3)
Q8. Currently, I am the principal investigator on one or more research grants:
(a) no 55 (63.2%) 22 (55.0) 33 (70.2) 26 (78.8) 29 (53.7) 27 (67.5) 28 (59.6)
(b) yes 32 (36.7%) 18 (45.0) 14 (29.8) 7 (21.2) 25 (46.3) 13 (32.5) 19 (40.4)
Q9. In my hospital, doctors are given more reward for:
(a) clinical skills with patients 63 (79.7%) 28 (75.7) 35 (83.3) 29 (87.9) 34 (73.9) 29 (82.9) 34 (77.3)
(b) contributing to scientific knowledge 16 (20.3%) 9 (24.3) 7 (16.7) 4 (12.1) 12 (26.1) 6 (17.1) 10 (22.7)
Q10. When a patient on a protocol relapses or progresses and the protocol dictates additional treatment that the patient does not want, I:
(a) encourage the patient to stay on the trial 28 (33.7%) 11 (28.2) 17 (38.6) 11 (33.3) 17 (34.0) 13 (35.1) 15 (32.6)
(b) remove the patient from the trial 55 (66.3%) 28 (71.8) 27 (61.4) 22 (66.7) 33 (66.0) 24 (64.9) 31 (67.4)
Q11. In general, patients are referred to me because of my:
(a) research activities 3 (3.5%) 2 (5.1) 1 (2.1) 1 (3.0) 2 (3.8) 2 (5.0) 1 (2.2)
(b) clinical reputation 83 (96.5%) 37 (94.9) 46 (97.9) 32 (97.0) 51 (96.2) 38 (95.0) 45 (97.8)
Q12. I participate more actively in professional organisations that are based on:
(a) my clinical speciality 74 (87.1%) 29 (76.3) 45 (95.7) 32 (97.0) 42 (80.8) 35 (89.7) 39 (84.8)
(b) my research activities 11 (12.9%) 9 (23.7) 2 (4.3) 1 (3.0) 10 (19.2) 4 (10.3) 7 (15.2)
Q13. The time I devote to publications, lectures and research commitments, compared with clinical work, is relatively:
(a) low 74 (86.0%) 31 (79.5) 43 (91.5) 32 (97.0) 42 (79.2) 34 (85.0) 40 (87.0)
(b) high 12 (14.0%) 8 (20.5) 4 (8.5) 1 (3.0) 11 (20.8) 6 (15.0) 6 (13.0)
Q14. The need for detailed monitoring of individual clinicians’ activities deters me from participating in randomised clinical trials:
(a) no 72 (82.8%) 37 (92.5) 35 (74.5) 24 (72.7) 48 (88.9) 32 (80.0) 40 (85.1)
(b) yes 15 (17.2%) 3 (7.5) 12 (25.5) 9 (27.3) 6 (11.1) 8 (20.0) 7 (14.9)
Q15. When a potentially eligible patient chooses not to enrol on a trial that I have suggested, I:
(a) often feel disappointed 26 (30.2%) 11 (27.5) 15 (32.6) 10 (30.3) 16 (30.2) 6 (15.4) 20 (42.6)
(b) seldom feel disappointed 60 (69.8%) 29 (72.5) 31 (67.4) 23 (69.7) 37 (69.8) 33 (84.6) 27 (57.4)
Q16. I devote a lot of time to educating other clinicians about randomised clinical trials:
(a) no 60 (69.0%) 21 (52.5) 39 (83.0) 27 (81.8) 33 (61.1) 27 (67.5) 33 (70.2)
(b) yes 27 (31.0%) 19 (47.5) 8 (17.0) 6 (18.2) 21 (38.9) 13 (32.5) 14 (29.8)
Q17. Frequent publications are important to my career advancement:
(a) agree 45 (52.3%) 21 (52.5) 24 (52.2) 14 (42.4) 31 (58.5) 22 (56.4) 23 (48.9)
(b) disagree 41 (47.7%) 19 (47.5) 22 (47.8) 19 (57.6) 22 (41.5) 17 (43.6) 24 (51.1)
Q18. When a protocol includes a treatment that is more aggressive than I would usually give to similar non-trial patients:
(a) I am often reluctant to participate 27 (31.4%) 14 (35.0) 13 (28.3) 8 (24.2) 19 (35.8) 11 (28.2) 16 (34.0)
(b) it makes no difference 59 (68.6%) 26 (65.0) 33 (71.7) 25 (75.8) 34 (64.2) 28 (71.8) 31 (66.0)
Q19. I am reluctant to participate in a trial that may randomise the patient to a ‘no treatment’ group:
(a) agree 18 (20.7%) 5 (12.5) 13 (27.7) 11 (33.3) 7 (13.0) 14 (35.0) 4 (8.5)
(b) disagree 69 (79.3%) 35 (87.5) 34 (72.3) 22 (66.7) 47 (87.0) 26 (65.0) 43 (91.5)
Q20. After being randomised, if a patient refuses the treatment to which he or she has been assigned:
(a) I accept the patient’s decision 71 (81.6%) 28 (70.0) 43 (91.5) 28 (84.8) 43 (79.6) 35 (87.5) 36 (76.6)
(b) I make every effort to keep the patient on the trial 16 (18.4%) 12 (30.0) 4 (8.5) 5 (15.1) 11 (20.4) 5 (12.5) 11 (23.4)
Q21. Overall I feel the quality of patient care:
(a) increases when patient is in a clinical trial 83 (98.8%) 40 (100) 43 (97.7) 30 (96.8) 53 (100) 38 (97.4) 45 (100)
(b) decreases when patient is in a clinical trial 1 (1.2%) 0 (0) 1 (2.3) 1 (3.2) 0 (0) 1 (2.6) 0 (0)
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sTable 1 (Continued)
Overall
Sample (%)
Physician (%)
(n¼40)
Surgeon (%)
(n¼47)
DGH (%)
(n¼33)
Specialist (%)
(n¼54)
Breast/colorectal
(%) (n¼40)
Other cancer type
(%) (n¼47)
Q22. When published data and my clinical experience conflict, I am more likely to rely on:
(a) my clinical experience 49 (59.0%) 20 (52.6) 29 (64.4) 22 (71.0) 27 (51.9) 24 (61.5) 25 (56.8)
(b) published data 34 (41.0%) 18 (47.4) 16 (35.6) 9 (29.0) 25 (48.1) 15 (38.5) 19 (43.2)
Q23. The more frequent obstacle to the successful completion of a clinical trial is:
(a) clinicians’ reluctance to participate 57 (67.1%) 27 (67.5) 30 (66.7) 17 (53.1) 40 (75.4) 26 (68.4) 31 (66.0)
(b) patients’ reluctance to participate 28 (32.9%) 13 (32.5) 15 (33.3) 15 (46.9) 13 (24.5) 12 (31.6) 16 (34.0)
Q24. If written informed consent were not required, I would approach more patients to enter clinical trials:
(a) true 16 (18.4%) 5 (12.5) 11 (23.4) 5 (15.1) 11 (20.4) 10 (25.0) 6 (12.8)
(b) false 71 (81.6%) 35 (87.5) 36 (76.6) 28 (84.8) 43 (79.6) 30 (75.0) 41 (87.2)
Q25. The opinions of the referring clinician regarding randomised clinical trials affects my decision to approach an eligible patient:
(a) true 14 (16.3%) 5 (12.5) 9 (19.6) 5 (15.1) 9 (17.0) 8 (20.5) 6 (12.8)
(b) false 72 (83.7%) 35 (87.5) 37 (80.4) 28 (84.8) 44 (83.0) 31 (79.5) 41 (87.2)
Q26. The thought of having to spell out all the details of a trial to eligible patients discourages me from approaching them to participate:
(a) true 20 (23.0%) 7 (17.5) 13 (27.7) 9 (27.3) 11 (20.4) 13 (32.5) 7 (14.9)
(b) false 67 (77.0%) 33 (82.5) 34 (72.3) 24 (72.7) 43 (79.6) 27 (67.5) 40 (85.1)
Q27. It is more important for me to be well-known among:
(a) local colleagues 56 (70.0%) 24 (63.2) 32 (76.2) 28 (90.3) 28 (57.1) 28 (82.4) 28 (60.9)
(b) national/international colleagues 24 (30.0%) 14 (36.8) 10 (23.8) 3 (9.7) 21 (42.9) 6 (17.6) 18 (39.1)
Q28. I spend the following amount of my time in research-related activities:
(a) less than one-third 75 (86.2%) 31 (77.5) 44 (93.6) 33 (100) 42 (77.8) 35 (87.5) 40 (85.1)
(b) one-third or more 12 (14.2%) 9 (22.5) 3 (6.4) 0 (0) 12 (22.2) 5 (12.5) 7 (14.9)
Q29. A major reason for my participation in randomised clinical trials is that it benefits my institution:
(a) agree 43 (49.4%) 20 (50) 23 (48.9) 14 (42.4) 29 (53.7) 21 (52.5) 22 (46.8)
(b) disagree 44 (50.6%) 20 (50) 24 (51.1) 19 (57.6) 25 (46.3) 19 (47.5) 25 (53.2)
Q30. Overall, participation in a randomised clinical trial is:
(a) an asset to my reputation 84 (100%) — — — — — —
(b) a liability to my reputation 0 (0%) — — — — — —
Q31. If I could have only one measure, I would assess how successful I was as a physician by:
(a) my research contributions 12 (14.0%) 8 (20.5) 4 (8.5) 1 (3.0) 11 (20.8) 5 (12.5) 7 (15.2)
(b) how I helped individual patients 74 (86.0%) 31 (79.5) 43 (91.5) 32 (97.0) 42 (79.2) 35 (87.5) 39 (84.8)
Q32. When I am personally uncertain as to which treatment is best, I am likely to:
(a) enter the patient in a randomised clinical trial if one exists 74 (86.0%) 38 (95.0) 36 (78.3) 27 (84.4) 47 (87.0) 33 (82.5) 41 (89.1)
(b) personally select a treatment 12 (14.0%) 2 (5.0) 10 (21.7) 5 (15.6) 7 (13.0) 7 (17.5) 5 (10.9)
Q33. When I obtain informed consent:
(a) I allow patient reaction to influence the content of the information given 50 (57.5%) 22 (55.0) 28 (59.6) 22 (66.7) 28 (51.9) 25 (62.5) 25 (53.2)
(b) I do not vary the content of the information given 37 (42.5%) 18 (45.0) 19 (40.4) 11 (33.3) 26 (48.1) 15 (37.5) 22 (46.8)
Q34. If research activities were to enhance my income, I would enter more patients in randomised clinical trials:
(a) agree 28 (32.5%) 12 (30.0) 16 (34.8) 12 (36.4) 16 (30.2) 14 (35.9) 14 (29.8)
(b) disagree 58 (67.5%) 28 (70.0) 30 (65.2) 21 (63.6) 37 (69.8) 25 (64.1) 33 (70.2)
Q35. I am more likely to attend a conference that focuses on:
(a) clinical issues 61 (76.3%) 23 (62.2) 38 (88.4) 28 (90.3) 33 (67.3) 27 (77.1) 34 (75.6)
(b) research issues 19 (23.7%) 14 (37.8) 5 (11.6) 3 (9.7) 16 (32.6) 8 (22.9) 11 (24.4)
Q36. In the past 3 years, I have authored/co-authored:
(a) 0 publications 12 (13.7%) 9 (22.5) 3 (6.4) 8 (24.2) 4 (7.4) 7 (17.5) 5 (10.6)
(b) 1–5 publications 51 (58.6%) 19 (47.5) 32 (68.1) 21 (63.6) 30 (55.6) 27 (67.5) 24 (51.1)
(c) 6–9 publications 14 (16.1%) 7 (17.5) 7 (14.9) 2 (6.1) 12 (22.2) 4 (10.0) 10 (21.3)
(d) 10 or more publications 10 (11.4%) 5 (12.5) 5 (10.6) 2 (6.1) 8 (14.8) 2 (5.0) 8 (17.0)
Q37. When informing patients about their prognosis, I find statistics:
(a) helpful 78 (90.7%) 36 (92.3) 42 (89.4) 28 (87.5) 50 (92.6) 36 (90.0) 42 (91.3)
(b) not helpful 8 (9.3%) 3 (7.7) 5 (10.6) 4 (12.5) 4 (7.4) 4 (10.0) 4 (8.7)
Q38. When making critical and controversial decisions I usually:
(a) seek major input from my patients 83 (96.5%) 39 (97.5) 44 (95.7) 33 (100) 50 (94.3) 37 (94.9) 46 (97.9)
(b) do not seek major input from my patients 3 (3.5%) 1 (2.5) 2 (4.3) 0 (0) 3 (5.7) 2 (5.1) 1 (2.1)
Q39. I think the patient’s right to select treatment options is always more important than the advancement of scientific knowledge:
(a) true 73 (83.9%) 32 (80.0) 41 (87.2) 25 (75.8) 48 (88.9) 33 (82.5) 40 (85.1)
(b) false 14 (16.1%) 8 (20.0) 6 (12.8) 8 (24.2) 6 (11.1) 7 (17.5) 7 (14.9)
Q40. If I had to choose, I would say my primary task is:
(a) caring for individual patients 82 (95.3%) 36 (92.3) 46 (97.9) 33 (100) 49 (92.5) 38 (95.0) 44 (95.7)
(b) contributing to scientific knowledge 4 (4.6%) 3 (7.7) 1 (2.1) 0 (0) 4 (7.5) 2 (5.0) 2 (4.3)
Q41. I would rather be somewhat:
(a) too involved with my patients 75 (87.2%) 37 (92.5) 38 (82.6) 26 (81.25) 49 (90.7) 34 (87.2) 41 (87.2)
(b) too detached from my patients 11 (12.8%) 3 (7.5) 8 (17.4) 6 (18.75) 5 (9.3) 5 (12.8) 6 (12.8)
Q42. When I participate in a randomised clinical trial, it is more likely that I:
(a) increase my patient population 72 (91.1%) 36 (94.7) 36 (87.8) 26 (86.7) 46 (93.9) 32 (91.4) 40 (90.9)
(b) lose patients I might otherwise keep 7 (8.9%) 2 (5.3) 5 (12.2) 4 (13.3) 3 (6.1) 3 (8.6) 4 (9.1)
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snational or international, rather than local, colleagues. These
differences suggest that those at specialist centres may be more
research oriented than those at DGHs.
Differences by geographical region
There were some regional differences in answers to questionnaire
items, but after exploration of confounders, it was found that the
effect of region (SE vs N and SW) disappeared when specialist
centre was added to the model.
Differences by type of MDT
Multi-disciplinary teams were grouped into breast and colorectal
teams vs the other teams (haematology, gynaecology, lung,
lymphoma, upper gastro-intestinal, and urology). This grouping
was chosen because breast and colorectal cancer are areas where
there are typically many clinical trials and where recruitment
has been common (UK Clinical Research Network, 2010).
We hypothesised that MDTs treating such patients may be more
favourable to clinical research. Table 4 shows the questionnaire
items which best differentiate clinicians by their MDT specialty.
These results suggest that breast and colorectal teams may be less
disappointed about not enrolling patients in a trial and more
accepting of trials with no-treatment arms. Interestingly, clinicians
belonging to other types of teams reported stronger publications
records and were more desirous of international rather than local
recognition.
Research orientation
Binary responses to questions 6, 7, 8, 12, 13, 16, 17, 27, 28, 31, 35,
36, and 40 (highlighted in bold in Table 1) were summed to form
the research-orientation scale. Full data were available from 74
participants and scores on the scale ranged from 0 to 12. The
numbers of observations with these 13 values were 18, 23, 7, 8, 4, 4,
1, 1, 1, 2, 3, 1, and 1, respectively, showing a skew towards the non-
research orientation end of the scale. Ordinal regression analysis
demonstrated that the probability of a high research orienta-
tion was greater in physicians vs surgeons (Po0.001) and in
respondents from a specialist centre (Po0.001) but little demon-
strable effect was associated with MDT type (breast/colorectal vs
rest: P¼0.06). Both the physician/surgeon and specialist/DGH
centre classifications retained their significance in a multivariate
analysis but MDT type demonstrated no relationship with research
orientation (Table 5).
Table 1 (Continued)
Overall
Sample (%)
Physician (%)
(n¼40)
Surgeon (%)
(n¼47)
DGH (%)
(n¼33)
Specialist (%)
(n¼54)
Breast/colorectal
(%) (n¼40)
Other cancer type
(%) (n¼47)
Q43. When there is controversy in the literature as to which treatment is best:
(a) I enter the patient in a clinical trial if one exists 79 (90.8%) 38 (95.0) 41 (87.2) 28 (84.8) 51 (94.4) 34 (85.0) 45 (95.7)
(b) I personally select a treatment for the patient 8 (9.2%) 2 (5.0) 6 (12.8) 5 (15.2) 3 (5.6) 6 (15.0) 2 (4.3)
Abbreviation: DGH¼district general hospital. Items highlighted in bold are used in the research-orientation score.
Table 2 Items distinguishing between physicians and surgeons
Questionnaire Item Physicians Surgeons Beta (sig.)
Q1. Ideally, clinicians are able to increase survival and improve the quality of patients’ lives. In cases where only one can be achieved at the cost of the other, I feel more satisfied when
I can:
(a) improve patients’ quality of life 29 (74%) 42 (91%) 1.29 (0.04)
(b) prolong patients’ lives 10 (26%) 4 (9%)
Q5. I enter the following amount of my potentially eligible patients into randomised clinical trials:
(a) under 50% 25 (62.5%) 41 (87%) 1.44 (0.02)
(b) 50% or more 15 (37.5%) 6 (13%)
Q35. I am likely to attend a conference that focuses on:
(a) clinical issues 23 (62%) 38 (88%) 1.63 (0.006)
(b) research issues 14 (38%) 5 (12%)
Table 3 Items distinguishing between clinicians in specialist centres and those in district general hospitals
Questionnaire Item DGH Specialist centre Beta (sig.)
Q19. I am reluctant to participate in a trial that may randomise the patient to a ‘no treatment’ group:
(a) agree 11 (33%) 7 (13%) 1.21 (0.03)
(b) disagree 22 (67%) 47 (87%)
Q23. The more frequent obstacle to the successful completion of a clinical trial is:
(a) clinicians’ reluctance to participate 17 (53%) 40 (76%)  1.00 (0.04)
(b) patients’ reluctance to participate 15 (47%) 13 (24%)
Q27. It is more important for me to be well known among:
(a) local colleagues 28 (90%) 28 (57%) 1.95 (o0.004)
(b) national/international colleagues 3 (10%) 21 (43%)
Abbreviation: DGH¼district general hospital.
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sDISCUSSION
Recruitment of patients into clinical trials is essential if progress is
to be made in improving cancer care. Despite this, recruitment is
often poor with studies slow to complete and with only a small
proportion of cancer patients being enrolled in studies. The
process of recruitment involves discussion between the patient and
their doctor but is preceded by identification of suitable patients
fulfilling eligibility criteria and then the doctor’s decision to offer
the patient an appropriate trial. The attitude of doctors is therefore
a critical part of the enrolment process.
This study evaluated doctors’ attitudes to clinical research and
to clinical trial recruitment. Using the Clinicians’ Attitudes to
Clinical Trials of Cancer Therapy Questionnaire the attitudes of 87
clinicians with a range of specialties, tumour site interests,
geographical location, and affiliations were assessed. The ques-
tionnaire also allowed clinicians to be allocated a research
orientation score.
The results indicate that research orientation was greater in
physicians than surgeons, with physicians more likely to enter
patients into trials and more likely to attend research-focussed
conferences. The lesser research orientation found in surgeons
may reflect the paucity of surgical trials available and the
difficulties encountered recruiting patients into a surgical trial.
One study of US breast cancer surgeons showed that 26% did
not discuss trials with any breast cancer patients, and a further
39% discussed trials with fewer than 10%. Surgeons identified
inadequate infrastructure and lack of time as significant deterrents
in trial participation (Schroen and Brenin, 2008). Klabunde et al
(2011) also show significantly lower clinical trial recruitment
among surgeons compared with oncologists although surgical
oncologists were more likely to participate in clinical trials than
general surgeons. Furthermore, surgeons showed the same pattern
as physicians with increased trial participation being associated
with academic affiliation, teaching of medical students, having a
more specialist clinical practice, and more frequent attendance at
multidisciplinary meetings.
It may be that although surgeons are a crucial part of a cancer
team, they feel they have a remote role in recruiting patients to
medical/oncological trials. The increasing number of neo-adjuvant
and peri-operative trials makes this untenable. Furthermore, it can
be argued that the surgeon has a pivotal role in influencing
patients’ expectations about the cancer treatments on offer
following surgery. The way the surgeon introduces the idea of
trials in general can facilitate any discussions, which follow with
the oncologist. If trials are treated as a ‘team business’, all team
members should be made aware of what trials are available for
patients in that tumour site and have the skills and knowledge
necessary to discuss these trials with patients.
The finding that clinicians at specialist centres are more
research oriented than those in DGHs is not surprising. Specialist
centres have more staff and resources available for trials and are
more likely to be set up to facilitate the running of trials. For
example, in a DGH there may be only one histopathologist dealing
with several cancer sites and who does not have any protected time
to deal with ‘trial’ tissue blocks in the tight timelines that some
trials have. Specialist centres may also be attached to research
institutions and therefore their staff is more likely to have a
teaching or research focus. Research-oriented clinicians may self-
select into posts within specialist centres or teaching hospitals. It is
interesting that clinicians working in specialist centres seem more
aware that clinician reluctance could be a barrier to the successful
completion of a clinical trial. This may result in clinicians in
specialist centres being more aware of their communication
training needs and more likely to address their own personal
barriers to trial recruitment.
Furthermore, ability to find trial information, and the familiarity
of investigators with trials, may differ in different types of hospital.
According to one survey, the most common reason cited for
physician non-participation in trials was a lack of knowledge about
available trials (Taylor, 2004). A review of US publicly funded trials
suggested that ‘encouraging the development of a user-friendly,
transparent, up-to-date, and easily accessible centralised registry
could improve both physician and patient awareness of the
available trials. In combination with electronic tools, such as,
clinical decision support software, a centralised registry could cue
physicians to important, applicable clinical trials at the point of
care’ (Nass et al, 2010, p. 204). A centralised system of trial
information available to all clinicians, whatever type of institution
they worked in, would potentially overcome some barriers to
recruitment in DGHs.
Table 4 Items distinguishing between MDTs
Questionnaire item Breast and colorectal Others Beta (sig.)
Q15. When a potentially eligible patient chooses not to enrol on a trial that I have suggested I:
(a) often feel disappointed 6 (15%) 20 (43%) 1.40 (0.0008)
(b) seldom feel disappointed 33 (85%) 27 (57%)
Q19. I am reluctant to participate in a trial that may randomise a patient to a ‘no treatment’ group.
(a) agree 14 (35%) 4 (09%)  1.76 (0.005)
(b) disagree 26 (65%) 43 (91%)
Q36. In the past 3 years, I have authored/co-authored:
(a) 0 7 (17%) 5 (11%) (a)(b) vs (c)(d) 1.38 (0.03)
(b) 1–5 27 (68%) 24 (51%)
(c) 6–9 4 (10%) 10 (21%)
(d) 10+ 2 (5%) 8 (17%)
Q27. It is more important for me to be well known among:
(a) local colleagues 28 (82%) 28 (61%)  1.10 (0.04)
(b) national/international colleagues 6 (18%) 18 (39%)
Abbreviation: MDT¼multi-disciplinary team.
Table 5 Multivariate ordinal regression analysis of clinical/research-
orientation scale
Variable Coefficient
Standard
error
Significance
level
Physician/surgeon 0.69 0.11 o0.001
Specialist/DGH 0.95 0.13 o0.001
Breast/colorectal vs other 0.03 0.11 0.78
Abbreviation: DGH¼ district general hospital.
Clinicians’ attitudes to clinical trials
E Ford et al
1541
British Journal of Cancer (2011) 104(10), 1535–1543 & 2011 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sLack of clinical trial support has been frequently cited as a
barrier to clinical trial involvement (Somkin et al, 2005; Schroen
and Brenin, 2008) but this issue does not explain the findings in
this study as all the MDTs involved in the study were supported by
the Wales Cancer Trials Network whose infrastructure (research
nurse time, data management support, etc.) was available to all
team members. Other papers refer to lack of reimbursement for
clinical trial work and other financial constraints as a barrier to
recruitment (Klabunde et al, 2011). Again this was not relevant to
this study, which took place in a health service (NHS) where all
staff are salaried.
Our hypothesis that clinicians working in breast and colorectal
cancer teams would be more research oriented was not borne out by
the data. Although these clinicians were more accepting of no-
treatment arms and more sanguine about patients declining trial
entry, they were less likely to seek national or international
recognition and had fewer publications compared with clinicians
treating other cancer sites. It appears then that specialty by cancer site
is not a marker of research orientation. As new therapies are required
across all types of cancer, it may be that clinicians specialising in all
tumour sites have a broadly equal interest in research, because of the
constantly emerging treatments in their field.
The research-orientation scale showed a strong skew towards
the non-research orientation end of the scale, with the majority of
participants scoring 0 or 1 out of a possible 13. However, despite
the skew, in ordinal analyses scores on this scale were significantly
different between surgeons and physicians, and between those
working in specialist centres and in DGHs, confirming our
findings from the single question analyses. This scale can therefore
be used in future studies to investigate clinician orientation
towards research in general and trials in particular, and could
potentially be used to evaluate training materials designed to
increase research interest and participation among clinicians.
There are several limitations to this study. The clinicians
assessed were all members of recognised cancer MDTs and were
involved in regular discussion of patient management. In Wales,
all clinical trial recruitment is recorded centrally and MDTs with
no recognised trial recruitment were excluded as this was an
explicit entry criterion for the associated trial. It is therefore
possible that the attitudes expressed are more favourable towards
research than would be seen in the general clinical population, as
MDTs with no trial experience were excluded.
Second, the questions on attitudes in this study asked primarily
about attitudes to RCTs and not to earlier, phase 1 and 2 trials.
Clinicians may have different attitudes to early phase trials, which
have different aims and require specialist infrastructure. Third,
only a small range of clinician characteristics, such as specialty,
were available. Clinician attitudes may also vary by other clinician
characteristics, such as number of patients seen per month,
clinician sex, training status, previous experience as principal
investigator, time since graduation, or academic or industry
affiliations (Joffe and Weeks, 2002). In addition, the clinician
sample in this study was culturally homogenous and therefore
cultural or ethnic differences in attitudes could not be explored.
Findings may be different in a more multicultural sample. It is also
possible that clinician attitudes may depend on the sociodemo-
graphic characteristics of their patient population. Further
research in this area would be interesting and may be useful
in increasing understanding about current recruitment practices.
In conclusion, this study gives us greater understanding of
clinicians’ attitudes to clinical trials, in order to target the problem
of low and selective accrual. Despite an increase in overall
recruitment to trials over the past 5 years, patients’ understanding
of them and health professionals’ explanations about them are still
problematic. There is a crucial need for all cancer team members
to be fully supportive and aware of the trials that are available in
their centres, and for all to receive and deliver consistent
information to patients and their relatives. The results of this
study are part of a larger project, in which members from
participating MDTs have taken part in training. The training has
addressed problems such as team dynamics acting as a barrier to
trial recruitment, inconsistent team communication, and the
difficulty of talking about trials where patients are unenthusiastic
about joining for different reasons. Previous research has shown
that communication skills training can also alter the attitudes and
beliefs of clinicians (Jenkins and Fallowfield, 2002). The overall
aims of this work are to increase the number of patients offered a
trial by clinicians, and to increase the quality of communication
about trials when they are discussed.
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